TesofensinevsVK2735

Tesofensine is a novel triple monoamine reuptake inhibitor (TRI) that simultaneously blocks the presynaptic reuptake transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT). Originally developed by NeuroSearch as NS2330 for neurodegenerative diseases, it was repurposed for obesity after clinical trials for Alzheimer's and Parkinson's disease unexpectedly revealed significant weight loss in treated patients.

The weight loss mechanism involves all three monoamine systems working in concert. Serotonin (5-HT) reuptake inhibition increases serotonergic tone in the hypothalamic appetite centers, particularly the paraventricular nucleus and ventromedial hypothalamus. Elevated synaptic serotonin activates 5-HT2C receptors on POMC neurons, promoting the release of alpha-MSH, which activates MC4R and produces satiety. This is the same pathway targeted by lorcaserin (Belviq), but tesofensine adds two additional mechanisms. Norepinephrine reuptake inhibition activates alpha-1 and beta-adrenergic receptors in the lateral hypothalamus, reducing appetite and increasing sympathetic nervous system activity, which raises basal metabolic rate and thermogenesis.

The dopamine reuptake inhibition component may be the most important differentiator. By increasing dopamine availability in the mesolimbic reward pathway (nucleus accumbens, ventral tegmental area), tesofensine may reduce the drive for food reward-seeking behavior — the compulsive eating of palatable, high-calorie foods that is mediated by dopamine signaling in the same circuits involved in addiction. This addresses a component of obesity that pure appetite suppressants miss: the hedonic (pleasure-driven) eating that overrides homeostatic satiety signals. Phase II clinical trials demonstrated remarkable efficacy — the 0.5 mg dose produced approximately 12.8 kg weight loss over 6 months, roughly double what GLP-1 receptor agonists typically achieve — though cardiovascular monitoring is necessary due to increases in heart rate associated with the noradrenergic and dopaminergic effects.

VK2735 is a once-weekly subcutaneous dual GLP-1/GIP receptor agonist with a structure optimised for high potency and a clean tolerability profile. Dual incretin receptor activation produces complementary effects on appetite, glucose handling, and energy expenditure: GLP-1 receptor agonism delivers central appetite suppression through hypothalamic arcuate-nucleus signalling, slows gastric emptying, and triggers glucose-dependent insulin secretion, while GIP receptor activation amplifies the insulin response, supports beta-cell function, and modulates adipose tissue lipid handling.

The molecule's pharmacokinetic profile delivers sustained receptor exposure across a one-week dosing interval, achieved through structural modifications that enable albumin binding and resistance to proteolytic degradation. In the Phase 2 VENTURE trial, the 15 mg dose produced 14.7% mean body weight loss at 13 weeks — the fastest early weight loss observed for any obesity drug, with the loss curve still descending steeply at trial end. This rapid trajectory suggests substantially greater total weight loss would be achievable with longer dosing, and Phase 3 VANQUISH trials launched in 2026 are testing 68-week treatment durations to characterise the full magnitude of effect.

Viking is also developing an oral tablet formulation of VK2735 in parallel, which entered Phase 1 in 2024-2025. If both formulations succeed, Viking would have one of the most flexible GLP-1/GIP product profiles on the market — though as a small biotech company it faces significant manufacturing and commercial scaling challenges relative to Lilly and Novo Nordisk.